Key facts
- GeniPhys’s last known valuation is $10.0M (Feb 2026).
- It has raised $9.4M across 2 recorded rounds; the latest was Seed Round ($3.0M) in Jan 2026.
- Notable investors include Plug and Play Tech Center, US National Science Foundation, MedTech Innovator, Elevate Ventures, Purdue Research Foundation — 7 tracked in total.
- GeniPhys has filed 2 Form Ds with the SEC since 2022, most recently Feb 2026 ($3.0M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for GeniPhys
Funding rounds
2 roundsAbout GeniPhys
Developer of a polymerizable collagen product designed to support site-appropriate tissue generation without evoking inflammation. The company's technology supports the custom design and fabrication of collagen materials for improving tissue restoration and regeneration, enabling medical researchers to provide potential material applications that extend from regenerative tissue replacements to the delivery of pharmaceutical and cell-based therapies.
- Sector
- Healthcare
- HQ
- Indianapolis, IN, United States
- Founded
- 2014
- Employees
- 8
- Website
- geniphys.com/
- Ownership
- Privately Held (backing)
GeniPhys doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GeniPhys shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GeniPhys in its N-PORT filings yet. We sweep new filings monthly.